Previous Article | Next Article ![]()
Mol Cell Biol, February 1998, p. 960-966, Vol. 18, No. 2
Unité Propre de Recherche 9003 du Centre National de
la Recherche Scientifique, Cancérogenèse et
Mutagenèse Moléculaire et Structurale, Ecole
Supérieure de Biotechnologie de Strasbourg (ESBS), 67400 Illkirch, France
Received 25 July 1997/Returned for modification 28 August
1997/Accepted 19 November 1997
The replication of double-stranded plasmids containing a single
N-2-acetylaminofluorene (AAF) adduct located in a short,
heteroduplex sequence was analyzed in Saccharomyces
cerevisiae. The strains used were proficient or deficient for the
activity of DNA polymerase
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Analysis of Damage Tolerance Pathways in Saccharomyces
cerevisiae: a Requirement for Rev3 DNA Polymerase in
Translesion Synthesis
(REV3 and
rev3
, respectively) in a mismatch and nucleotide excision repair-defective background (msh2
rad10
).
The plasmid design enabled the determination of the frequency with
which translesion synthesis (TLS) and mechanisms avoiding the adduct by
using the undamaged, complementary strand (damage avoidance mechanisms) are invoked to complete replication. To this end, a hybridization technique was implemented to probe plasmid DNA isolated from individual yeast transformants by using short, 32P-end-labeled
oligonucleotides specific to each strand of the heteroduplex. In both
the REV3 and rev3
strains, the two strands of an unmodified heteroduplex plasmid were replicated in ~80% of the
transformants, with the remaining 20% having possibly undergone prereplicative MSH2-independent mismatch repair. However,
in the presence of the AAF adduct, TLS occurred in only 8% of the
REV3 transformants, among which 97% was mostly error free
and only 3% resulted in a mutation. All TLS observed in the
REV3 strain was abolished in the rev3
mutant, providing for the first time in vivo biochemical evidence of a
requirement for the Rev3 protein in TLS.
*
Corresponding author. Mailing address: UPR 9003 du
CNRS, ESBS, Blvd. Sébastien Brant, 67400 Illkirch, France. Phone:
33 03 88 65 53 45. Fax: 33 03 88 65 53 43. E-mail:
fuchs{at}esbs.u-strasbg.fr.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|